Danaher stock beats Wall Street dip as investors eye Fed minutes and Jan. 28 earnings

Danaher stock beats Wall Street dip as investors eye Fed minutes and Jan. 28 earnings

NEW YORK, December 29, 2025, 22:23 ET — Market closed

  • Danaher shares were last up about 0.1% at $230.63.
  • The stock held up better than major U.S. indexes in thin year-end trade.
  • Traders are watching Tuesday’s Fed minutes and Danaher’s Jan. 28 earnings call.

Danaher Corp shares were last up about 0.1% at $230.63 on Monday, after trading between $229.26 and $231.77 during the session.

The muted move still mattered for Danaher investors because the stock held up in a market that turned lower as the year winds down and liquidity thins, a setup that can amplify sector rotations.

It also comes ahead of a key macro catalyst: the Federal Reserve’s December meeting minutes, due Tuesday, with traders pricing in additional rate cuts in 2026 as the U.S. dollar weakens into year-end. Reuters

U.S. stocks fell on Monday, led by losses in megacap technology. The Dow dropped 0.51%, the S&P 500 fell 0.35% and the Nasdaq slid 0.50%; “In light volume trading, we’re seeing a reversal of what we saw over the last couple of days,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management. Reuters

In Danaher’s life-sciences tools peer group, Thermo Fisher rose 0.75%, while Agilent slipped 0.29%, Waters fell 0.25% and Illumina edged down 0.34%, a mixed tape that left stock-pickers leaning on company-specific catalysts rather than broad sector momentum.

Danaher, a major supplier of life-sciences instruments and diagnostics tests, is often treated as a read-through on lab spending — a line item that can tighten quickly when biopharma customers rein in budgets.

Lower interest-rate expectations can support the valuation of steady cash-generating healthcare names, while a softer dollar can help companies with sizable overseas sales when foreign revenue is translated back into dollars.

On the company calendar, Danaher said it will webcast its fourth-quarter 2025 earnings call on Jan. 28 at 8 a.m. ET, with its earnings release and related materials posted earlier that morning. Danaher

Before Tuesday’s session, investors will focus on the Fed minutes alongside the S&P Case-Shiller home price index and the Chicago Business Barometer, in a holiday-shortened week with few major corporate earnings on the calendar. Investopedia

With markets closed Thursday for New Year’s Day and year-end flows still moving, traders expect lighter liquidity into midweek — a backdrop that can push single-stock moves beyond what the day’s headlines might normally justify.

For Danaher shares, traders will be watching whether the stock holds the $229 area flagged by Monday’s low and whether it can retest the $232 zone after the session high.

The next decisive catalyst for Danaher remains its Jan. 28 results and outlook, when investors will be looking for updates on order trends, margins and the pace of demand from biopharma and laboratory customers.

Stock Market Today

  • Smart Growth Stocks to Buy With $2,000 Right Now on the TSX
    December 29, 2025, 10:45 PM EST. Robin Brown highlights three TSX growth names to deploy a $2,000. Mainstreet Equity (MEQ) offers a real estate compounder with a value-add strategy and a valuation near multi-year lows, backed by ample liquidity for acquisitions. Descartes Systems Group (DSG) has posted record 2025 results, with revenue up 11% and EBITDA up 15%, a 45% EBITDA margin, and a net cash-rich balance sheet, even as shares sit at a low valuation not seen since 2020. VitalHub (VHI) is a smaller healthcare software name delivering 214% five-year gains, serving public health systems in Canada, the U.K., the Middle East, and Australia. Taken together, these names illustrate opportunities in a challenging market driven by cash flow strength and long-term growth potential into 2026.
Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus
Previous Story

Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit
Next Story

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Go toTop